ACE and chronic kidney disease: In the ACE inhibitor (ACEI)/angiotensin receptor blocker (ARB) and pre-end-stage renal disease (pre-ESRD) program cohort, 207 MgO users and 1,401 non-users were included; after matching, 151 MgO users and 302 non-users remained.